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Abstract: Reaction of 3-amino-2-alkylquinazolin-4(3H)-ones 
with several chiral acid chlorides was found to be dependent on 
the molar proportions.  When a 1:1 molar mixture was heated 
under reflux, the corresponding 3-(diacylamino)- derivatives were 
obtained in poor yields.  However, when a 2:1 molar mixture was 
reacted in refluxing toluene, the 3-acylamino- derivatives were 
obtained in good yields based on the acid chloride.  Lithiation of 
the 3-acylamino-2-alkylquinazolin-4(3H)-ones was achieved by 
the use of LDA in anhydrous THF at –78 °C and the reaction was 
regioselective at the carbon α to position 2 of the quinazolin-
4(3H)-one moiety.  The dilithio reagents thus obtained reacted 
with electrophiles to give the corresponding 2-substituted deriva-
tives in very good yields.  The NMR spectra of the products show 
the expected diastereotopism for all the CH2 groups and provide 
evidence for long-range asymmetric induction. 
Key words: lithiation, quinazolin-4(3H)-ones, dilithio reagent, 
asymmetric induction, diastereotopism 
Directed metallation2,3 has found wide use in regioselec-
tive introduction of functional substituents into aromatic 
and heterocyclic compounds.  However, there are rela-
tively few examples concerning directed metallation of 
quinazolin-4(3H)-ones to afford more complex substi-
tuted derivatives.4-13  Compounds possessing this ring 
system are of interest because they show a variety of 
biological activities.14  In continuation of our own inter-
est in the use of lithiation reactions for organic synthe-
sis,15 we have demonstrated the lithiation of various 
quinazolin-4(3H)-ones,6-8 including simple 3-acylamino 
derivatives.9,10  We now report a study of the scope of 
the lithiation reaction for more complex 3-acylamino-2-
alkylquinazolin-4(3H)-ones containing chiral acyl units.  
We have been able to achieve regioselective lithiation of 
a range of such quinazolin-4(3H)-ones by the use of 
LDA, and the synthesis of more complex 2-substituted 
derivatives in good yields.  The products also show evi-
dence of long-range asymmetric induction. 
The first stage of this study required the synthesis of 
representative chiral 3-acylamino-2-alkylquinazolin-
4(3H)-ones.  Initially, reactions of 3-amino-2-
ethylquinazolin-4(3H)-one (1)16 with chiral but racemic 
acid chlorides in the presence of triethylamine at 0 °C or 
room temperature were attempted.  However, 1 was 
recovered unchanged, suggesting that no reaction had 
occurred under these conditions.  A series of experiments 
was conducted in which the reaction conditions were 
varied in an attempt to produce the corresponding 
acylamino derivatives.  When a 1:1 molar mixture of 1 
and an acid chloride in the presence of triethylamine was 
heated under reflux in anhydrous toluene for 1 h the 
corresponding diacylamino derivative 2 or 3 was ob-
tained in 41% or 25% isolated yield, respectively 
(Scheme 1).  The monoacylamino derivative (5 or 8) was 
formed in only low yield and a substantial quantity of 
unreacted 1 remained. 
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    1 2 R
1 = OPh, R2 = Me (41%)
3 R1 = Ph, R2 = Et (25%)  
Scheme 1  
Product 2 appeared from its NMR spectra as a mixture of 
two racemic diastereoisomers in unequal proportions, 
while product 3 appeared from its 1H NMR spectrum as 
a pair of racemic diastereoisomers in approximately 
equal proportions.  The 1H NMR spectrum of 3 showed 
diastereotopism for the hydrogens of the CH2 groups at 
position 2 and in the acyl units.  
In a modified procedure for the attempted synthesis of a 
chiral 3-acylamino-2-alkylquinazolin-4(3H)-one a 2:1 
molar mixture of 3-amino-2-ethylquinazolin-4(3H)-one 
(1) and 2-phenoxypropanoyl chloride was heated under 
reflux in anhydrous toluene for 1 h in the presence of 
triethylamine.  Work-up gave the desired product 5 in 
78% yield.  Therefore, these conditions were applied in 
the synthesis of a range of products (5-10, Scheme 2) 
derived from both 1 and 3-amino-2-propylquinazolin-
4(3H)-one (4)17 with a variety of acid chlorides.  This 
procedure afforded products 5-10 in very good yields 
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Scheme 2  
 
Table 1 Synthesis of products 5-10 According to Scheme 2 
Compound R R1 R2 Yield (%)a 
5 Me Me OPh 78 
6 Me Me 1-Naphthyl 74 
7 Me Et OPh 80 
8 Me Et Ph 79 
9 Et Me OPh 90 
10 Et Et OPh 93 
 
a Yields of isolated, purified products based on acid chloride added. 
 
Products 5-10 appear from their NMR spectra as mix-
tures of two diastereoisomers in unequal proportions, 
due to restricted rotation around the N-N axis.18  The 
spectra also showed diastereotopism for the CH2 protons 
of the ethyl and propyl groups (see experimental section 
for details).  The 1H NMR spectra were temperature 
dependent and showed some evidence of equilibration at 
55-60 °C in CDCl3.  In DMSO-d6, the spectra showed a 
single set of signals at 150 °C in all cases. 
In order to introduce more complex substituents at posi-
tion 2, lithiations of 5-10 were carried out.  Lithiation 
was achieved by the use of LDA in anhydrous THF at 
-78 °C under nitrogen and the reaction was regioselec-
tive at the carbon α to position 2 of the quinazolin-
4(3H)-one moiety.  Addition of one equivalent of LDA 
presumably produced the monolithio reagents 11, which 
were converted into the dilithio reagents 12 on addition 
of a second equivalent of LDA.  Reactions of the dilithio 
reagents 12 with several electrophiles (benzophenone, 
benzaldehyde, acetophenone, 2-butanone) afforded the 
corresponding 2-substituted quinozolin-4(3H)-ones 13-
27 (Scheme 3) in very good yields (Table 2) following 
column chromatography. 
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The NMR spectra of all products containing a CH2 group 
either in the side chain at position 2 or in the acylamino 
group (compounds 17-27) showed the expected di-
astereotopism for the CH2 protons.  In addition, the spec-
tra (of the total product obtained following chromatogra-
phy to remove coloured impurities) revealed the pres-






































Scheme 3  
Table 2 Synthesis of Products 13-27 According to Scheme 3 
Compound R R1 R2 E Yield (%)a 
13 Me Me OPh Ph2C(OH) 80 
14 Me Me OPh PhCH(OH) 82 
15 Me Me OPh PhC(OH)Me 78 
16 Me Me 1-naphthyl Ph2C(OH) 79 
17 Me Et OPh Ph2C(OH) 76 
18 Me Et OPh PhCH(OH) 80 
19 Me Et  OPh PhC(OH)Me 79 
20 Me Et Ph Ph2C(OH) 77 
21 Me Et Ph EtC(OH)Me 75 
22 Et Me OPh Ph2C(OH) 88 
23 Et Me OPh PhCH(OH) 76 
24 Et Me OPh PhC(OH)Me 80 
25 Et Et OPh Ph2C(OH) 90 
26 Et Et OPh PhCH(OH) 80 
27 Et Et OPh PhC(OH)Me 78 
 
a Yields of isolated, purified (column chromatography) products. 
 
The number of diastereoisomers of the product expected 
when benzophenone is used as the electrophile is four.  
Indeed, it was found that the NMR spectra of products 
13, 22 and 25 showed a mixture of the expected four 
diastereoisomers in unequal proportions.  However, the 
NMR spectra of products 17 and 20 showed the pre-
dominant presence of two substantial diastereoisomers in 
unequal proportions, while in the case of product 16, 




Product 13 was separated into two fractions by crystalli-
sation.  The first fraction (13a, 60%) showed the pres-
ence of a single diastereoisomer.  The x-ray crystallogra-
phy of this compound (Figure 1) indicated the presence 
of one THF molecule for each molecule of 13a.  The 
THF appeared to be hydrogen-bonded to the NH proton 
of the acylamino group.  The crystal structure also 
showed that this isomer was 2-((1S*)-2,2-diphenyl-2-
hydroxy-1-methyl)-3-((2R*)-2-
phenoxypropionylamino)quinazolin-4(3H)-one with 
(Ra*) configuration about the N-N axis.  The second 
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fraction (40%) showed the presence of all four diastereo-
isomers, with 13a being a minor component. 
 
Figure 1 X-ray crystal structure of 13a with numbered crystallo-
graphic atoms 
Variable temperature 1H NMR of 13a up to 60 °C in 
CDCl3 showed only minimal line broadening.  However, 
a sample of 13a left at room temperature for many 
months, showed a 1H NMR spectrum corresponding to a 
mixture of 13a and one other diastereoisomer, presuma-
bly the one involving the alternative stereochemistry 
(Sa*) about the N-N axis.  This enabled identification of 
the two diastereoisomers having the same configuration 
at the new asymmetric carbon atom.  The 1H NMR spec-
trum of the second fraction (mixture) showed that these 
two components accounted for about 18% of the frac-
tion, i.e. about 7% of the total product, bringing the total 
amount of the isomers having that stereochemistry at the 
new asymmetric carbon atom to around 67%.  The other 
two diastereoisomers, having the alternative configura-
tion at the new asymmetric carbon atom, accounted for 
the remaining 33% or so.  Therefore, the new asymmet-
ric centre is formed with a 2:1 stereoselectivity.  Al-
though this selectivity is relatively small, it is neverthe-
less noteworthy, since it represents a long-range asym-
metric inductive effect (the two asymmetric carbon at-
oms have a 1,6-relationship). 
For product 17, the two major diastereoisomers both had 
the same configuration at the new asymmetric carbon 
atom.  This was deduced by the fact that the newly cre-
ated CH signals for those two isomers in the 1H NMR 
spectrum began to coalesce at 60 °C.  Furthermore, the 
chemical shift positions were virtually identical to those 
for 13a and its N-N isomer.  The two major diastereoi-
somers accounted for about 80% of the total, leading to 
the conclusion that the long-range asymmetric induction 
produced a ratio of configurations at the new centre of 
ca. 4:1. 
For products 16 and 20, the NMR signals were more 
difficult to resolve and it was therefore much more diffi-
cult to identify the individual diastereoisomers with any 
confidence, although it was clear, particularly from the 
13C NMR spectra, that two diastereoisomers were pre-
dominant.  At 60 °C the 1H NMR spectra showed some 
line broadening, but it was still not clear whether the two 
major isomers had different configurations at the new 
asymmetric carbon atoms or whether they differed about 
the N-N axis. 
When an unsymmetrical carbonyl compound (benzalde-
hyde, acetophenone or 2-butanone) is used as electro-
phile, the number of diastereoisomers expected to be 
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formed is eight.  The ambient temperature NMR spectra 
of 21 (2-butanone used as the electrophile) showed the 
presence of at least seven racemic diastereoisomers in 
unequal proportions.  However, the ambient temperature 
NMR spectra of products 14, 15, 18, 19 and 24 showed 
mixtures of no more than four substantial diastereoisom-
ers in unequal proportions.  Furthermore, for this group 
of products, the 1H NMR spectra recorded at 100 °C 
showed the presence of only two major diastereoisomers 
in unequal proportions, which indicates equilibration via 
rotation about the N-N axis.  In the case of products 23, 
26 and 27 the ambient temperature NMR spectra showed 
mixtures of only two significant diastereoisomers in 
unequal proportions, which indicates a considerable 
long-range asymmetric induction.  Unfortunately, an 
attempt to bring about equilibration in these cases by 
recording the 1H NMR at 150 °C resulted in some de-
composition to give bezaldehyde or acetophenone. 
In conclusion, lithiation of chiral 3-acylamino-2-
alkylquinazolin-4(3H)-ones followed by reactions with 
carbonyl compounds is useful for the elaboration of 
more complex 2-substituted 3-acylaminoquinazolin-
4(3H)-ones, and in some cases gives considerable long-
range asymmetric induction at the newly created asym-
metric centre(s).  This opens up possibilities for novel 
synthetic approaches to certain types of chiral com-
pounds, which we intend to investigate. 
Melting point determinations were performed by the 
open capillary method using a Gallenkamp melting point 
apparatus and are reported uncorrected.  The laboratories 
of the University of Wales Cardiff carried out micro-
analyses.  1H and 13C NMR spectra were recorded on a 
Bruker AC400 spectrometer operating at 400 MHz for 
1H and 100 MHz for 13C measurements.  Chemical shifts 
are reported relative to tetramethylsilane.  Assignments 
of signals are based on coupling patterns and expected 
chemical shift values and have not been rigorously con-
firmed.  Signals with similar characteristics might be 
interchanged.  Low-resolution mass spectra were re-
corded on a VG 12-253 spectrometer, electron impact 
(EI) at 70 eV and chemical ionization (CI) by the use of 
ammonia as ionization gas.  FAB mass spectra were 
recorded on a VG-Autospec instrument.  Accurate mass 
data were obtained on a VG ZAB-E instrument.  Column 
chromatography was carried out using Merck Kieselgel 
60 (230-400 mesh).  Lithium diisopropylamide (LDA) 
and other chemicals were obtained from Aldrich Chemi-
cal Company and used without further purification.  THF 
was distilled from sodium benzophenone ketyl.  Other 
solvents were purified by standard procedures.19,20 
 
3-(Diacylamino)-2-ethylquinazolin-4(3H)-ones (2) and 
(3); General Procedure 
To a stirred mixture of 1 (1.9 g, 10 mmol) and Et3N (5 
mL) in anhydrous toluene (20 mL), was added a solution 
of the appropriate acid chloride (11 mmol) in anhydrous 
toluene (5 mL).  The mixture was heated under reflux for 
30 min, allowed to cool, washed with sat. aq. NaHCO3 
(2 x 10 mL) and H2O (2 x 15 mL), dried (MgSO4), and 
evaporated under reduced pressure.  The residue ob-
tained was purified by column chromatography on silica 




mp 104-107 °C; pair of racemic diastereoisomers; 2a/2b 
= 3:5 (1H NMR). 
FAB-MS: m/z (%) = 508 (M+ + Na, 20), 486 (MH+, 67), 
392 (10), 338 (31), 216 (33), 121 (100). 
HRMS: m/z calcd for C28H28N3O5 (MH+): 486.2029; 
found: 486.2017. 
Compound 2a 
1H NMR (CDCl3): δ = 8.17 (dd, J = 8, 1 Hz, 1 H, H5), 
7.69 (app. dt, J = 8, 1 Hz, 1 H, H7), 7.48 (d, J = 8 Hz, 1 
H, H8), 7.41 (app. dt, J = 8, 1 Hz, 1 H, H6), 7.26-6.74 
(m, 10 H, 2 OPh), 5.43 (q, J = 6.5 Hz, 2 H, 2 CH), 2.27 
(q, J = 7 Hz, 2 H, CH2), 1.52 (d, J = 6.5 Hz, 6 H, 2 
CH3CH), 1.09 (t, J = 7 Hz, 3 H, CH3CH2). 
13C NMR (CDCl3): δ = 172.6 (s, C=O), 160.2 (s, C4), 
157.1 (s, C2), 156.8 (s, C1 of 2 OPh), 146.6 (s, C8a), 
135.2 (d, C7), 129.7 (d, C3 of OPh), 127.6 (d, C5), 127.0 
(d, C6), 126.8 (d, C8), 122.4 (d, C4 of OPh), 120.3 (s, 
C4a), 115.3 (d, C2 of OPh), 72.9 (d, CH), 25.5 (t, CH2), 
17.8 (q, CH3CH), 9.7 (q, CH3CH2). 
Compound 2b 
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1H NMR (CDCl3): δ = 8.17 (dd, J = 8, 1 Hz, 1 H, H5), 
6.69 (app. dt, J = 8, 1 Hz, 1 H, H7), 7.53 (d, J = 8 Hz, 1 
H, H8), 7.41 (app. dt, J = 8, 1 Hz, 1 H, H6), 7.26-6.60 
(m, 10 H, 2 OPh), 5.83 (q, J = 6.5 Hz, 2 H, 2 CH), 2.31 
(q, J = 7 Hz, 2 H, CH2), 1.64 (d, J = 6.5 Hz, 6 H, 2 
CH3CH), 1.18 (t, J = 7 Hz, 3 H, CH3CH2). 
13C NMR (CDCl3): δ = 171.8 (s, C=O), 160.2 (s, C4), 
157.2 (s, C2), 155.7 (s, C1 of OPh), 146.6 (s, C8a), 
135.3 (d, C7), 129.6 (d, C3 of OPh), 127.7 (d, C5), 127.1 
(d, C6), 126.8 (d, C8), 122.0 (d, C4 of OPh), 120.3 (s, 
C4a), 115.0 (d, C2 of OPh), 73.4 (d, CH), 25.6 (t, CH2), 




mp 155-156 °C; pair of racemic diastereoisomers 
(NMR). 
FAB-MS: m/z (%) = 504 (M+ + Na, 23), 482 (MH+, 69), 
336 (86), 216 (36), 190 (36), 119 (100). 
HRMS: m/z calcd for C30H32N3O3 (MH+): 482.2444; 
found: 482.2459. 
1H NMR (CDCl3): δ = 8.30 (dd, J = 8, 1 Hz, 1 H, H5), 
7.80 (app. dt, J = 8, 1 Hz, 1 H, H7), 7.68 (d, J = 8 Hz, 1 
H, H8), 7.50 (app. dt, J = 8, 1 Hz, 1 H, H6), 7.33 (m, 4 
H, H3 of 2 Ph), 7.12 (m, 4 H, H2 of 2 Ph), 6.70 (d, J = 
7.5 Hz, 2 H, H4 of 2 Ph), 4.98, 3.23 (2 t, J = 7 Hz, 2 H, 2 
CH), 2.24, 2.14 (2 dq, J = 14, 7 Hz, 2 H, CH2CH3), 1.85-
1.68 (m, 2 H, CH2CH), 1.30-0.93 (m, 2 H, CH2CH), 
0.93, 0.80 (2 t, J = 7 Hz, 6 H, 2 CH3CH2CH), 0.57 (t, J = 
7 Hz, 3 H, CH3CH2). 
13C NMR (CDCl3): δ = 174.2, 173.9 (2 s, C=O), 160.4 
(s, C4), 158.2 (s, C2), 147.0 (s, C8a), 137.8, 136.6 (2 s, 
C1 of Ph), 135.3 (d, C7), 129.0, 128.9 (2 d, C3 of Ph), 
128.5, 128.4 (2 d, C4 of Ph), 127.8, 127.7 (2 d, C2 of 
Ph), 127.5 (d, C5), 127.4 (d, C6), 126.8 (d, C8), 120.5 (s, 
C4a), 54.0, 53.5 (2 d, CH), 27.7, 27.0 (2 t, CH2CH), 24.3 





To a stirred mixture of 1 or 4 (10 mmol) and Et3N (3 
mL) in anhydrous toluene (20 mL), was added a solution 
of the appropriate acid chloride (5 mmol) in anhydrous 
toluene (5 mL).  The mixture was heated under reflux for 
30 min, allowed to cool, washed with sat. aq. NaHCO3 
(2 x 10 mL) and H2O (2 x 15 mL), dried (MgSO4), and 
evaporated under reduced pressure.  The residue ob-
tained was purified by column chromatography on silica 
gel (Et2O-hexane, 1:4) to give the corresponding 
3-acylamino derivatives 5-10.  The yields obtained are 




mp 90-92 °C; 5a/5b = 1:2 (1H NMR). 
Anal. Calcd for C19H19N3O3: C, 67.65; H, 5.64; N, 
12.46.  Found: C, 67.6; H, 5.6; N, 12.6. 
EI-MS: m/z (%) = 337 (M+, 22), 244 (13), 216 (100), 
173 (32), 130 (34), 121 (81), 77 (99). 
HRMS: m/z calcd for C19H19N3O3 (M+): 337.1426; 
found: 337.1426. 
Compound 5a 
1H NMR (CDCl3): δ = 8.73 (s, exch., 1 H, NH), 8.16 (dd, 
J = 8, 1 Hz, 1 H, H5), 7.72 (m, 1 H, H7), 7.64 (d, J = 8 
Hz, 1 H, H8), 7.41 (app. dt, J = 8, 1 Hz, 1 H, H6), 7.35 
(t, J = 7.5 Hz, 2 H, H3 of OPh), 7.07 (t, J = 7.5 Hz, 2 H, 
H2 of OPh), 6.99 (d, J = 7.5 Hz, 1 H, H4 of OPh), 4.97 
(q, J =7 Hz, 1 H, CH), 2.44 (2 dq, J = 15, 7.5 Hz, 2 H, 
CH2), 1.81 (d, J = 7 Hz, 3 H, CH3CH), 1.06 (t, J = 7.5 
Hz, 3 H, CH3CH2). 
13C NMR (CDCl3): δ = 172.8 (s, C=O), 159.9 (s, C4), 
158.5 (s, C2), 156.8 (s, C1 of OPh), 147.0 (s, C8a), 
134.8 (d, C7), 129.9 (d, C3 of OPh), 127.5 (d, C5), 126.9 
(d, C6), 126.7 (d, C8), 122.5 (d, C4 of OPh), 120.6 (s, 
C4a), 115.2 (d, C2 of OPh), 74.7 (d, CH), 27.0 (t, CH2), 
18.8 (q, CH3CH), 10.5 (q, CH3CH2). 
Compound 5b 
1H NMR (CDCl3): δ = 8.93 (s, exch., 1 H, NH), 8.12 (d, 
J = 8 Hz, 1 H, H5), 7.72 (m, 1 H, H7), 7.64 (d, J = 8 Hz, 
1 H, H8), 7.41 (app. dt, J = 8, 1 Hz, 1 H, H6), 7.35 (t, J = 
7.5 Hz, 2 H, H3 of OPh), 7.07 (t, J = 7.5 Hz, 2 H, H2 of 
OPh), 6.99 (d, J = 7.5 Hz, 1 H, H4 of OPh), 4.95 (q, J = 
7 Hz, 1 H, CH), 2.81 (2 dq, J = 15, 7.5 Hz, 2 H, CH2), 
1.68 (d, J = 7 Hz, 3 H, CH3CH), 1.34 (t, J = 7.5 Hz, 3 H, 
CH3CH2). 
13CNMR (CDCl3): δ = 172.6 (s, C=O), 159.9 (s, C4), 
158.4 (s, C2), 156.8 (s, C1 of OPh), 147.0 (s, C8a), 
134.8 (d, C7), 129.9 (d, C3 of OPh), 127.5 (d, C5), 126.9 
(d, C6), 126.7 (d, C8), 122.9 (d, C4 of OPh), 120.7 (s, 
C4a), 116.5 (d, C2 of OPh), 75.8 (d, CH), 26.8 (t, CH2), 





mp 180-182 °C; 6a/6b = 5:6 (13C NMR). 
EI-MS: m/z (%) = 371 (M+, 5), 216 (40), 182 (38), 155 
(100), 153 (34), 130 (15), 115 (9), 90 (8), 76 (10). 
CI-MS: m/z (%) = 372 (MH+, 7), 217 (9), 175 (100), 159 
(7), 91 (6). 
HRMS: m/z calcd for C23H21N3O2 (MH+): 371.1634; 
found: 371.1634. 
1H NMR (CDCl3): δ = 8.20-7.37 (m, 12 H, ArH and 
NH), 4.71-4.62 (m, 1 H, CH), 2.54-2.28 (m, 2 H, CH2), 
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1.89, 1.74 (2 d, J = 7 Hz, 3 H, CH3CH), 0.99 (t, J = 7.5 
Hz, 3 H, CH3CH2). 
Compound 6a 
13C NMR (CDCl3): δ = 175.0 (s, C=O), 160.2 (s, C4), 
158.8 (s, C2), 146.9 (s, C8a), 136.0 (s, C1′), 134.8 (d, 
C7), 133.8 (s, C4′a), 131.1 (s, C8′a), 129.1 (d, C5′), 
128.7 (d, C5), 127.8 (d, C6), 126.8 (d, C8), 126.7 (d, 
C3′), 126.5 (d, C2′), 126.1 (d, C4′), 125.8 (d, C7′), 124.9 
(d, C6′), 123.2 (d, C8′), 120.6 (s, C4a), 42.0 (d, CH), 
26.8 (t, CH2), 17.7 (q, CH3CH), 10.5 (q, CH3CH2). 
Compound 6b 
13C NMR (CDCl3): δ = 174.9 (s, C=O), 160.0 (s, C4), 
158.7 (s, C2), 146.9 (s, C8a), 136.0 (s, C1′), 134.7 (d, 
C7), 134.2 (s, C4′a), 131.1 (s, C8′a), 129.2 (d, C5′), 
128.5 (d, C5), 127.3 (d, C6), 126.8 (d, C8), 126.7 (d, 
C3′), 126.5 (d, C2′), 126.2 (d, C4′), 125.9 (d, C7′), 125.6 
(d, C6′), 122.8 (d, C8′), 120.5 (s, C4a), 42.0 (d, CH), 




mp 93-94 °C; 7a/7b = 1:2 (1H NMR). 
Anal. Calcd for C20H21N3O3: C, 68.36; H, 6.02; N, 11.96.  
Found: C, 68.4; H, 6.2; N, 11.8. 
EI-MS: m/z (%) = 351 (M+, 10), 258 (7), 230 (13), 216 
(60), 173 (40), 135 (100), 107 (65), 94 (31), 77 (75), 41 
(43). 
CI-MS: m/z (%) = 352 (MH+, 10), 197 (25), 176 (18), 
175 (100), 136 (5), 105 (7), 58 (5). 
HRMS: m/z calcd for C20H21N3O3 (M+): 351.1583; 
found: 351.1583. 
Compound 7a 
1H NMR (CDCl3): δ = 8.69 (s, exch., 1 H, NH), 8.16 (d, 
J = 8 Hz, 1 H, H5), 7.73 (app. dt, J = 8, 1 Hz, 1 H, H7), 
7.60 (d, J = 8 Hz, 1 H, H8), 7.40 (t, J = 8 Hz, 1 H, H6), 
7.36 (t, J = 7.5 Hz, 2 H, H3 of OPh), 7.18-6.99 (m, 3 H, 
H2 and H4 of OPh), 4.78 (t, J = 7 Hz, 1 H, CH), 2.41 
(dq, J = 14, 7 Hz, 2 H, CH2CH), 2.18 (dq, J = 15, 7.5 Hz, 
2 H, CH2), 1.20 (t, J = 7 Hz, 3 H, CH3CH2CH), 1.02 (t, J 
= 7.5 Hz, 3 H, CH3CH2). 
13C NMR (CDCl3): δ = 172.1 (s, C=O), 159.9 (s, C4), 
158.5 (s, C2), 157.2 (s, C1 of OPh), 146. 9 (s, C8a), 
134.8 (d, C7), 129.9 (d, C3 of OPh), 127.0 (d, C5), 126.6 
(d, C6), 126.5 (d, C8), 122.4 (d, C4 of OPh), 120.5 (s, 
C4a), 115.1 (d, C2 of OPh), 79.5 (d, CH), 26.9 (t, 
CH2CH), 26.5 (t, CH2), 10.5 (q, CH3CH2CH), 9.5 (q, 
CH3CH2). 
Compound 7b 
1H NMR (CDCl3): δ = 8.88 (s, exch., 1 H, NH), 8.16 (d, 
J = 8 Hz, 1 H, H5), 7.43 (app. dt, J = 8, 1 Hz, 1 H, H7), 
7.60 (d, J = 8 Hz, 1 H, H8), 7.40 (t, J = 8 Hz, 1 H, H6), 
7.36 (t, J = 7.5 Hz, 2 H, H3 of OPh), 7.18-6.99 (m, 3 H, 
H2 and H4 of OPh), 4.78 (t, J = 7.4 Hz, 1 H, CH), 2.87 
(dq, J = 14, 7 Hz, 2 H, CH2CH), 2.08 (dq, J = 15, 7.5 Hz, 
2 H, CH2), 1.33 (t, 3 H, J = 7 Hz, CH3CH2CH), 1.11 (t, J 
= 7.5 Hz, 3 H, CH3CH2). 
13C NMR (CDCl3): δ = 172.1 (s, C=O), 159.8 (s, C4), 
158.3 (s, C2), 157.5 (s, C1 of OPh), 146. 9 (s, C8a), 
134.8 (d, C7), 127.4 (d, C3 of OPh), 127.0 (d, C5), 126.8 
(d, C6), 126.7 (d, C8), 122.9 (d, C4 of OPh), 120.6 (s, 
C4a), 116.7 (d, C2 of OPh), 80.9 (d, CH), 26.9 (t, 





mp 180-183 °C; 8a/8b = 1:3 (1H NMR). 
EI-MS: m/z (%) = 335 (M+, 5), 216 (40), 189 (17), 173 
(12), 119 (65), 91 (100). 
HRMS: m/z calcd for C20H21N3O2 (M+): 335.1634; 
found: 335.1634. 
Compound 8a 
1H NMR (DMSO-d6): δ = 11.66 (s, exch., 1 H, NH), 
8.10 (d, J = 8 Hz, 1 H, H5), 7.99 (t, J = 8 Hz, 1 H, H7), 
7.75 (t, J = 8 Hz, 1 H, H6), 7.52-7.30 (m, 6 H, H8 and 
Ph), 3.98 (t, J = 7 Hz, 1 H, CH), 3.00, 3.62 (2 dq, J = 14, 
7 Hz, 2 H, CH2CH), 2.22, 1.91 (2 dq, J = 15, 7.5 Hz, 2 
H, CH2), 1.05 (t, J = 7 Hz, 3 H, CH3CH2CH), 1.00 (t, J = 
7.5 Hz, 3 H, CH3CH2). 
13C NMR (DMSO-d6): δ = 173.7 (s, C=O), 167.8 (s, C4), 
155.9 (s, C2), 138.7 (s, C8a), 138.0 (s, C1 of Ph), 136.7 
(d, C7), 129.5 (d, C5), 128.8 (d, C3 of Ph), 128.3 (d, 
C6), 128.0 (d, C2 of Ph), 127.6 (d, C8), 120.1 (d, C4 of 
Ph), 118.5 (s, C4a), 52.3 (d, CH), 26.6 (t, CH2CH), 25.4 
(t, CH2), 12.1 (q, CH3CH2CH), 11.3 (q, CH3CH2). 
Compound 8b 
1H NMR (DMSO-d6): δ = 11.38 (s, exch., 1 H, NH), 
8.10 (d, J = 8 Hz, 1 H, H5), 7.99 (t, J = 8 Hz, 1 H H7), 
7.75 (t, J = 8 Hz, 1 H, H6), 7.52-7.30 (m, 6 H, H8 and 
Ph), 3.90 (t, J = 7 Hz, 1 H, CH), 3.34, 3.10 (2 dq, J = 14, 
7 Hz, 2 H, CH2CH), 2.22, 1.91 (2 dq, J = 15, 7.5 Hz, 2 
H, CH2), 1.44 (t, J = 7 Hz, 3 H, CH3CH2CH), 1.03 (t, J = 
7.5 Hz, 3 H, CH3CH2). 
13C NMR (DMSO-d6): δ = 173.8 (s, C=O), 167.6 (s, C4), 
155.7 (s, C2), 138.7 (s, C8a), 138.0 (s, C1 of Ph), 136.4 
(d, C7), 129.6 (d, C5), 128.6 (d, C3 of Ph), 128.3 (d, 
C6), 128.2 (d, C2 of Ph), 127.6 (d, C8), 120.2 (d, C4 of 
Ph), 118.5 (s, C4a), 52.7 (d, CH), 26.60 (t, CH2CH), 25.1 




mp 87-89 °C; 9a/9b = 1:2 (1H NMR). 
EI-MS: m/z (%) = 352 (M+ + 1, 12), 337 (M+, 20), 323 
(100), 285 (35). 
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CI-MS: m/z (%) = 352 (MH+, 16), 189 (100), 183 (32), 
91 (17). 
HRMS: m/z calcd for C20H22N3O3 (MH+): 352.1661; 
found: 352.1664. 
Compound 9a 
1H NMR (CDCl3): δ = 8.98 (s, exch., 1 H, NH), 8.17 (dd, 
J = 8, 1 Hz, 1 H, H5), 7.76-7.60 (m, 2 H, H7 and H8), 
7.42 (app. dt, J = 8, 1 Hz, 1 H, H6), 7.37-7.33 (m, 1 H, 
H3 of OPh), 7.10-7.06 (m, 1 H, H4 of OPh), 7.00 (d, J = 
7.5 Hz, 1 H, H2 of OPh), 4.96 (q, J = 7 Hz, 1 H, CH), 
2.79-2.73 (m, 2 H, CH2), 1.79 (d, J = 7 Hz, 3 H, 
CHCH3), 1.63-1.49 (m, 2 H, CH2), 1.05 (t, J = 7.5 Hz, 3 
H, CH3CH2). 
13C NMR (CDCl3): δ = 172.4 (s, C=O), 159.9 (s, C4), 
157.5 (s, C1 of OPh), 156.8 (s, C2), 146.9 (s, C8a), 
134.9 (d, C7), 129.9 (d, C3 of OPh), 126.9 (d, C5), 126.8 
(d, C6), 126.6 (d, C8), 122.8 (d, C4 of OPh), 120.7 (s, 
C4a), 116.5 (d, C2 of OPh), 75.7 (d, CH), 35.6 (t, CH2), 
20.0 (t, CH2), 18.7 (q, CH3CH), 13.9 (q, CH3CH2). 
Compound 9b 
1H NMR (CDCl3): δ = 8.75 (s, exch., 1 H, NH), 8.17 (dd, 
J = 8, 1 Hz, 1 H, H5), 7.76-7.60 (m, 2 H, H7 and H8), 
7.42 (app. dt, J = 8, 1 Hz,1 H, H6), 7.37-7.33 (m, 1 H, 
H3 of OPh), 7.10-7.06 (m, 1 H, H4 of OPh), 7.00 (d, J = 
7.5 Hz, 1 H, H2 of OPh), 4.94 (q, J = 7 Hz, 1 H, CH), 
2.44-2.38 (m, 2 H, CH2), 1.83 (d, J = 7 Hz, 3 H, 
CH3CH), 1.63-1.49 (m, 2 H, CH2), 0.80 (t, J = 7.4 Hz, 3 
H, CH3CH2). 
13C NMR (CDCl3): δ = 172.9 (s, C=O), 159.9 (s, C4), 
157.7 (s, C1 of OPh), 156.9 (s, C2), 146.9 (s, C8a), 
134.9 (d, C7), 130.0 (d, C3 of OPh), 127.4 (d, C5), 126.8 
(d, C6), 126.6 (d, C8), 122.5 (d, C4 of OPh), 120.5 (s, 
C4a), 116.5 (d, C2 of OPh), 74.6 (d, CH), 35.5 (t, CH2), 




mp 115-117 °C; 10a/10b = 1:2 (1H NMR). 
EI-MS: m/z (%) = 365 (M+, 4), 337 (6), 244 (15), 230 
(30), 187 (20), 173 (20), 160 (60), 135 (45), 117 (34), 
107 (40), 94 (43), 77 (100), 65 (35). 
CI-MS: m/z (%) = 366 (MH+, 30), 197 (32), 189 (100), 
173 (13), 136 (5), 105 (33). 
HRMS: m/z calcd for C21H24N3O3 (MH+): 366.1819; 
found: 366.1819. 
Compound 10a 
1H NMR (CDCl3): δ = 8.39 (s, exch., 1 H, NH), 8.16 (m, 
1 H, H5), 7.71 (m, 1 H, H7), 7.60 (d, J = 8 Hz, 1 H, H8), 
7.44-7.00 (m, 6 H, H6 and OPh), 4.81-4.77 (m, 1 H, 
CH), 2.74-2.70 (m, 2 H, CH2), 2.13-2.81 (m, 2 H, CH2), 
1.84-1.79 (m, 2 H, CH2), 1.12 (t, J = 7 Hz, 3 H, CH3), 
1.04 (t, J = 7.5 Hz, 3 H, CH3). 
13C NMR (CDCl3): δ = 172.1 (s, C=O), 159.8 (s, C4), 
157.5 (s, C1 of OPh), 157.5 (s, C2), 146.9 (s, C8a), 
134.8 (d, C7), 129.8 (d, C3 of OPh), 127.4 (d, C5), 126.8 
(d, C6), 126.6 (d, C8), 122.4 (d, C4 of OPh), 120.7 (s, 
C4a), 116.7 (d, C2 of OPh), 80.9 (d, CH), 35.7 (t, CH2), 
26.1 (t CH2), 20.0 (t, CH2), 13.8 (q, CH3), 9.1 (q, CH3). 
Compound 10b 
1H NMR (CDCl3): δ = 8.73 (s, exch., 1 H, NH), 8.16 (m, 
1 H, H5), 7.71 (m, 1 H, H7), 7.60 (d, J = 8 Hz, 1 H, H8), 
7.44-7.00 (m, 6 H, H6 and OPh), 4.81-4.77 (m, 1 H, 
CH), 2.35-2.31 (m, 2 H, CH2), 2.25-2.20 (m, 2 H, CH2), 
1.57-1.52 (m, 2 H, CH2), 1.21 (t, J = 7 Hz, 3 H, CH3), 
0.76 (t, J = 7.5 Hz, 3 H, CH3). 
13C NMR (CDCl3): δ = 172.2 (s, C=O), 159.9 (s, C4), 
157.7 (s, C1 of OPh), 157.3 (s, C2), 146.9 (s, C8a), 
134.8 (d, C7), 129.9 (d, C3 of OPh), 127.0 (d, C5), 126.8 
(d, C6), 126.6 (d, C8), 122.9 (d, C4 of OPh), 120.5 (s, 
C4a), 115.0 (d, C2 of OPh), 79.8 (d, CH), 35.5 (t, CH2), 
26.6 (t CH2), 19.8 (t, CH2), 13.6 (q, CH3), 9.6 (q, CH3). 
 
2-Substituted 3-Acylaminoquinazolin-4(3H)-ones (13-
27); General Procedure 
A solution of LDA in pentane (1.6 M; 1.3 mL, 2.2 mmol) 
was added under N2 in a dropwise manner to a stirred 
solution of the appropriate 3-acylamino-2-
alkylquinazolin-4(3H)-ones (5-10, 1 mmol) in anhydrous 
THF (10 mL) at -78 °C.  Formation of the dilithio re-
agent was observed as a very deep red solution.  The 
mixture was stirred at -78 °C for 30 min, after which an 
electrophile (1.1 mmol) (as a solution in anhydrous THF 
for benzophenone, otherwise neat) was added.  The mix-
ture was stirred for 2 h at -78 °C then removed from the 
cooling bath and allowed to warm to r.t., diluted with 
Et2O (10 mL), and quenched with sat. aq. NH4Cl solu-
tion (10 mL).  The organic layer was washed with H2O 
(2 x 20 mL), dried (MgSO4), and evaporated under re-
duced pressure.  The products obtained were purified by 
column chromatography on silica gel (Et2O-hexane, 1:4) 
to give the corresponding 2-substituted derivatives 13-27 






mp 172 °C; a single diastereoisomer (NMR). 
Anal. Calcd for C32H29N3O4.THF: C, 73.08; H, 6.30; N, 
7.10.  Found: C, 73.2; H, 6.2; N, 7.3. 
EI-MS: m/z (%) = 355 (5), 337 (10), 216 (42), 182 (49), 
173 (37), 121 (50), 105 (100), 77 (95), 51 (42). 
CI-MS: m/z (%) = 520 (MH+, 33), 357 (100), 338 (40), 
262 (20), 228 (15). 
HRMS: m/z calcd for C32H30N3O4 (MH+): 520.2236; 
found: 520.2206. 
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1H NMR (CDCl3): δ = 8.34 (s, exch., 1 H, NH), 8.09 (dd, 
J = 8, 1 Hz, 1 H, H5), 7.73 (app. dt, J = 8, 1 Hz, 1 H, 
H7), 7.61 (d, J = 8 Hz, 1 H, H8), 7.51-6.92 (m, 17 H, 
ArH and OH), 5.02 (q, J = 6.7 Hz, 1 H, CH), 4.00 (q, J = 
7 Hz, 1 H, CH), 3.75 (t, J = 6.5 Hz, 4 H, H2 of THF), 
1.86 (t, J = 6.5 Hz, 4 H, H3 of THF), 1.82 (d, J = 6.7 Hz, 
3 H, CH3), 1.30 (d, J = 7 Hz, 3 H, CH3). 
13C NMR (CDCl3): δ = 173.7 (s, C=O), 161.6 (s, C4), 
159.0 (s, C2), 157.2 (s, C1 of OPh), 147.6 (s, C8a), 
145.3, 144.3 (2 s, C1 of 2 Ph), 135.2 (d, C7), 130.4 (d, 
C3 of OPh), 128.1 (d, C5), 127.2 127.0 (2 d, C3 of 2 Ph), 
126.9 (d, C6), 126.6 (d, C8), 126.5, 125.5 (2 d, C2 of 2 
Ph), 124.7 (d, C4 of 2 Ph), 122.7 (d, C4 of OPh), 120.2 
(s, C4a), 114.4 (d, C2 of OPh), 79.2 (s, C-OH), 74.5 (d, 
CH), 68.0 (t, C2 of THF), 42.1 (d, CH), 25.6 (t, C3 of 




mp 171-173 °C; four diastereoisomers (NMR). 
Anal. Calcd for C32H29N3O4: C, 73.97; H, 5.63; N, 8.09.  
Found: C, 74.2; H, 5.6; N, 8.0. 
EI-MS: m/z (%) = 355 (6), 337 (12), 216 (42), 182 (30), 
173 (20), 121 (55), 105 (90), 77 (100), 51 (41). 
CI-MS: m/z (%) = 520 (MH+, 45), 357 (90), 338 (100). 
HRMS: m/z calcd for C32H30N3O4 (MH+): 520.2236; 
found: 520.2198. 
1H NMR (CDCl3): δ = 8.58, 8.55 (2 s, exch., 1 H, NH), 
8.09, 7.85 (2 dd, J = 8, 1 Hz, 1 H, H5), 7.80-6.85 (m, 19 
H, ArH and OH), 5.12, 5.02 (2 q, J = 7 Hz, 1 H, CH), 
4.36, 4.01, 3.96, 3.73 (4 q, J = 7 Hz, 1 H, CH), 1.94, 
1.86, 1.76 (3 d, J = 7 Hz, 3 H, CH3), 1.36, 1.30, 0.75 (3 
d, J = 7 Hz, 3 H, CH3). 
13C NMR (CDCl3): δ = 173.6, 173.4 (2 s, C=O), 161.5 
(s, C4), 159.1 (s, C2), 156.8 (s, C1 of OPh), 147.9 (s, 
C8a), 145.4, 145.0 (2 s, C1 of 2 Ph), 135.1 (d, C7), 
130.5, 130.2 (2 d, C3 of OPh), 128.4, 128.3, 128.1, 128.0 
(4 d, C3 of 2 Ph), 127.2, 127.1 (2 d, C5), 126.9, 126.8 (2 
d, C6), 126.4, 126.3 (2 d, C8), 126.0, 125.5 (2 d, C2 of 2 
Ph), 125.4, 125.0 (2 d, C4 of 2 Ph), 123.1, 122.5 (2 d, C4 
of OPh), 120.2 (s, C4a), 116.6, 114.4 (2 d, C2 of OPh), 
80.0, 79.3 (2 s, C-OH), 75.9, 74.6 (2 d, CH), 42.4, 41.9 





mp 90-93 °C; four diastereoisomers (NMR). 
EI-MS: m/z (%) = 337 (3), 216 (11), 173 (8), 130 (15), 
121 (33), 94 (29), 77 (100), 39 (41). 
CI-MS: m/z (%) = 444 (MH+, 10), 338 (5), 281 (41), 183 
(40), 175 (56), 122 (48), 91 (100), 74 (38). 
HRMS: m/z calcd for C26H26N3O4 (MH+): 444.1923; 
found: 444.1926. 
1H NMR (CDCl3): δ = 8.85, 8.75, 8.67, 8.61 (4 s, exch., 
1 H, NH), 8.11-6.82 (m, 14 H, ArH), 4.90 (m, 1 H, CH), 
4.79, 4.57 (2 d, J = 6 Hz, 1 H, CH), 4.03, 3.89 (2 br s, 
exch., 1 H, OH), 3.46, 3.15, 2.84 (3 pentet, J = 7 Hz, 1 
H, CH), 1.71, 1.61 (2 d, J = 7 Hz, 3 H, CH3), 1.22, 1.17, 
0.61 (3 d, J = 7 Hz, 3 H, CH3). 
13C NMR (CDCl3): δ = 172.9, 172.6, 172.1, 171.1 (4 s, 
C=O), 160.2, 160.1, 159.6 (3 s, C4), 159.6, 159.1 (2 s, 
C2), 156.8, 156.7 (2 s, C1 of OPh), 146.3, 146.2 (2 s, 
C8a), 142.7, 142.3, 141.7 (3 s, C1 of Ph), 135.1, 135.0, 
134.8 (3 d, C7), 128.6, 128.4 (2 d, C3 of OPh), 128.2, 
128.1 (2 d, C3 of Ph), 127.6, 127.2 (2 d, C5), 127.2, 
127.1 (2 d, C6), 127.0, 126.8 (2 d, C2 of Ph), 126.2, 
125.8 (2 d, C8), 122.7, 122.5, 122.4, 122.3 (4 d, C4 of 
Ph), 120.9, 120.7 (2 s, C4a), 116.3 (d, C4 of OPh), 114.9, 
114.6 (2 d, C2 of OPh), 78.5, 77.8, 77.2 (3 d, CH), 76.1, 
75.2, 74.6, 74.3 (4 d, CH), 43.5, 42.8, 42.6, 42.0 (4 d, 





mp 148-150 °C; four diastereoisomers (1H NMR). 
EI-MS: m/z (%) = 337 (6), 216 (37), 173 (20), 130 (15), 
121 (38), 105 (53), 94 (29), 77 (100). 
CI-MS: m/z (%) = 458 (MH+, 88), 338 (25), 295 (100). 
HRMS: m/z calcd for C27H28N3O4 (MH+): 458.2080; 
found: 458.2073. 
1H NMR (CDCl3): δ = 9.16, 9.11, 8.92, 8.88 (4 s, exch., 
1 H, NH), 8.23-6.90 (m, 14 H, ArH), 6.51, 6.15 (2 br s, 
exch., 1 H, OH), 5.06, 4.96 (2 q, J = 7 Hz, 1 H, CH), 
3.50, 3.30, 3.20, 3.00 (4 q, J = 7 Hz, 1 H, CH), 1.91, 
1.89, 1.78 (3 d, J = 7 Hz, 3 H, CH3) 1.64, 1.48, 1.21 (3 s, 
3 H, CH3), 1.11, 1.07, 1.02, 0.60 (4 d, J = 7 Hz, 3 H, 
CH3). 
13C NMR (CDCl3): δ = 172.3, 172.2, 171.9 (3 s, C=O), 
162.1, 161.8 (2 s, C4), 159.5, 159.4 (2 s, C2), 157.0, 
156.7, 156.6 (3 s, C1 of OPh), 146.3, 146.1 (2 s, C8a), 
145.5, 145.4, 145.3 (3 s, C1 of Ph), 135.3 (d, C7), 130.2, 
130.1 (2 d, C3 of OPh), 129.9, 128.2, 128.1 (3 d, C3 of 
Ph), 127.3, 127.2, 127.1 (3 d, C2 of Ph), 127.0, 126.8 (2 
d, C5), 126.5, 126.4 (2 d, C6), 124.9, 124.8, 124.7 (3 d, 
C8), 122.9, 122.6, 122.5 (3 d, C4 of Ph), 120.5 (s, C4a), 
116.5, 116.4 (2 d, C4 of OPh), 114.7, 114.6 (2 d, C2 of 
OPh), 77.4, 75.8, 75.4 (3 d, CH), 74.9, 74.6 (2 s, C-OH), 
44.6, 44.2 (2 d, CH), 30.0, 29.9 (2 q, CH3), 20.7, 19.2, 
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mp 131-133 ºC; two diastereoisomers in equal propor-
tions (1H NMR). 
EI-MS: m/z (%) = 372 (38), 371 (100), 356 (15), 355 
(61). 
CI-MS: m/z (%) = 554 (MH+, 100), 372 (20), 200 (75), 
183 (30). 
HRMS: m/z calcd for C36H32N3O3 (MH+): 554.2444; 
found: 554.2444. 
1H NMR (CDCl3): δ = 8.45-6.50 (m, 23 H, ArH, OH and 
NH), 4.75, 4.66 (2 q, J = 7 Hz, 1 H, CH), 3.78, 3.66 (2 q, 
J = 7 Hz, 1 H, CH), 2.03, 1.77 (2 d, J = 7 Hz, 3 H, CH3), 
1.26, 1.24 (2 d, J = 7 Hz, 3 H, CH3). 
13C NMR (CDCl3): δ = 177.3, 174.9 (2 s, C=O), 161.5, 
161.4 (2 s, C4), 159.6, 159.1 (s, C2), 147.2, 147.1 (2 s, 
C8a), 145.4, 145.3 (2 s, C1 of 2 Ph), 136.5 (s, C1′), 
135.2, 135.1 (2 d, C7), 134.2, 134.03 (2 s, C4′a), 132.1, 
130.9 (2 s, C8′a), 129.7, 129.5 (2 d, C5′), 129.2, 128.8 (2 
d, C5), 128.1, 127.8 (2 d, C3 of 2 Ph), 127.7, 127.2 (2 d, 
C2 of Ph), 127.1, 126.9 (2 d, C6), 126.9, 126.8 (2 d, C8), 
126.5, 126.4 (2 d, C3′), 126.2, 126.0 (2 d, C2′), 126.0, 
125.7 (2 d, C4′), 125.4, 125.3 (2 d, C7′), 124.4, 124.2 (2 
d, C6′), 124.3 (d, C4 of 2 Ph), 123.1, 122.6 (2 d, C8′), 
120.2 (s, C4a), 79.0, 78.9 (2 s, C-OH), 43.0, 42.1 (2 d, 





mp 183-184 °C; 17a/17b = 1:4 (1H NMR). 
Anal. Calcd for C33H31N3O4: C, 74.28; H, 5.86; N, 7.87.  
Found: C, 74.2; H, 5.7; N, 8.1. 
EI-MS: m/z (%) = 351 (4), 216 (12), 182 (35), 135 (22), 
105 (100), 77 (85), 51 (40). 
CI-MS: m/z (%) = 534 (MH+, 19), 357 (100). 
HRMS: m/z calcd for C33H32N3O4 (MH+): 534.2393; 
found: 534.2393. 
Compound 17a 
1H NMR (DMSO-d6): δ = 11.45 (s, exch., 1 H, NH), 
8.07 (dd, J = 8, 1 Hz, 1 H, H5), 7.77-6.86 (m, 19 H, ArH 
and OH), 4.94 (t, J = 7 Hz, 1 H, CH), 3.99 (q, J = 7 Hz, 
1 H, CH), 2.20 (m, 2 H, CH2), 1.16 (t, J = 7 Hz, 3 H, 
CH3), 0.90 (d, J = 7 Hz, 3 H, CH3). 
13C NMR (DMSO-d6): δ = 171.6 (s, C=O), 161.8 (s, C4), 
159.0 (s, C2), 157.5 (s, C1 of OPh), 148.1 (s, C8a), 
145.7, 144.6 (2 s, C1 of 2 Ph), 135.0 (d, C7), 129.1 (d, 
C3 of OPh), 127.9, 127.7 (2 d, C3 of 2 Ph), 127.0 (d, 
C5), 126.5 (d, C6), 126.4 (d, C8), 125.5 (d, C4 of 2 Ph), 
125.0, 124.8 (2 d, C2 of 2 Ph), 121.6 (d, C4 of OPh), 
120.2 (s, C4a), 115.5 (d, C2 of OPh), 78.7 (s, C-OH), 
77.7 (d, CH), 41.8 (d, CH), 26.1 (t, CH2), 14.0 (q, CH3), 
9.5 (q, CH3). 
Compound 17b 
1H NMR (DMSO-d6): δ = 11.74 (s, exch., 1 H, NH), 
8.07 (dd, J = 8, 1 Hz, 1 H, H5), 7.77-6.86 (m, 19 H, ArH 
and OH), 4.82 (t, J = 7 Hz, 1H, CH), 3.95 (q, J = 7 Hz, 1 
H, CH), 2.50 (m, 2 H, CH2), 1.22 (t, J = 7 Hz, 3 H, CH3), 
0.95 (d, J = 7 Hz, 3 H, CH3). 
13C NMR (DMSO-d6): δ = 172.6 (s, C=O), 162.3 (s, C4), 
158.2 (s, C2), 157.5 (s, C1 of OPh), 148.2 (s, C8a), 
145.1, 144.7 (2 s, C1 of 2 Ph), 135.0 (d, C7), 129.5 (d, 
C3 of OPh), 128.0, 127.8 (2 d, C3 of 2 Ph), 127.0 (d, 
C5), 126.5 (d, C6), 126.4 (d, C8), 125.9 (d, C4 of 2 Ph), 
125.1, 124.8 (2 d, C2 of 2 Ph), 121.7 (d, C4 of OPh), 
120.1 (s, C4a), 114.9 (d, C2 of OPh), 78.9 (s, C-OH), 
78.8 (d, CH), 41.1 (d, CH), 26.5 (t, CH2), 14.1 (q, CH3), 




mp 100-102 °C; four diastereoisomers (1H NMR). 
EI-MS: m/z (%) = 230 (6), 216 (28), 173 (32), 135 (44), 
105 (49), 94 (33), 77 (100). 
CI-MS: m/z (%) = 458 (MH+, 33%), 281 (70), 197 (40), 
175 (53), 136 (46), 114 (41), 105 (100), 94 (56). 
HRMS: m/z calcd for C27H28N3O4 (MH+): 458.2080; 
found: 458.2074. 
1H NMR (CDCl3): δ = 9.19, 9.08, 8.98, 8.72 (4 s, exch., 
1 H, NH), 8.04-6.51 (m, 14 H, ArH), 5.65, 5.52, 5.30, 
5.20 (4 s, exch., 1 H, OH), 4.79-4.19 (m, 2 H, 2 CH), 
3.37, 3.02, 2.71, 2.51 (4 pentet, J = 7 Hz, 1 H, CH), 
2.24-1.98 (m, 2 H, CH2), 1.32-0.96 (m, 3 H, CH3), 0.91, 
0.87, 0.46, 0.35 (4 d, J = 7 Hz, 3 H, CH3). 
13C NMR (CDCl3): δ = 171.2, 171.0 (2 s, C=O), 161.0, 
160.1 (2 s, C4), 159.0, 158.7 (2 s, C2), 157.5, 157.4 (2 s, 
C1 of OPh), 145.2, 145.0 (2 s, C8a), 143.9, 143.6, 143.6 
(3 s, C1 of Ph), 135.1 (d, C7), 129.6 (d, C3 of OPh), 
127.9, 127.8 (2 d, C3 of Ph), 127.7 (d, C5), 127.2 (d, 
C6), 127.0, 126.7 (2 d, C2 of Ph), 126.6, 125.4 (2 d, C4 
of Ph), 126.3 (d, C8), 121.6, 121.5 (2 d, C4 of OPh), 
121.4 (s, C4a), 115.6, 115.4, 115.1 (3 d, C2 of OPh), 
78.2, 78.0, 77.4 (3 d, CH), 73.7, 72.9 (2 d, CH), 42.9, 
42.6 (2 d, CH) 26.1, 26.0, 25.8 (3 t, CH2), 13.5, 13.2, 




mp 157-158 °C; four diastereoisomers (NMR). 
EI-MS: m/z (%) = 351 (54), 258 (29), 220 (52), 216 
(100), 202 (98), 189 (64). 
EI-MS: m/z (%) = 472 (MH+, 6), 295 (12), 175 (23), 138 
(100), 105 (32). 
HRMS: m/z calcd for C28H30N3O4 (MH+): 472.2236; 
found: 472.2239. 
11 PAPER  
Template for SYNLETT and SYNTHESIS © Thieme  Stuttgart · New York 2004-05-13 page 11 of 15 
1H NMR (CDCl3): δ = 8.91, 8.89, 8.76, 8.71 (4 s, exch., 
1 H, NH), 8.15-6.79 (m, 14 H, ArH), 5.60, 6.04 (2 br s, 
exch., 1 H, OH), 4.79-4.63 (m, 1 H, CH), 3.48, 3.21, 
3.11, 2.90 (4 q, J = 7 Hz, 1 H, CH), 2.14-1.98 (m, 2 H, 
CH2), 1.56, 1.54, 1.37, 1.35 (4 s, 3 H, CH3), 1.15, 1.13 (2 
t, J = 7 Hz, 3 H, CH3), 0.92, 0.51 (2 d, J = 7 Hz, 3 H, 
CH3). 
13C NMR (CDCl3): δ = 172.9, 172.8, 172.6 (3 s, C=O), 
162.1, 161.9, 161.8 (3 s, C4), 159.5, 159.4 (2 s, C2), 
157.4, 157.1 (2 s, C1 of OPh), 146.2, 146.1 (2 s, C8a), 
145.5, 145.3 (2 s, C1 of Ph), 135.3 (d, C7), 130.2, 130.1, 
130.0 (3 d, C3 of OPh), 128.2, 128.1 (2 d, C3 of Ph), 
127.3, 127.2 (2 d, C2 of Ph), 127.0 (d, C5), 126.5, 126.4 
(2 d, C6), 124.9, 124.8 (2 d, C8), 123.1, 122.6, 122.4 (3 
d, C4 of Ph), 120.6 (s, C4a), 116.8, 116.7 (2 d, C4 of 
OPh), 114.7, 114.6 (2 d, C2 of OPh), 81.0, 80.8, 79.9, 
79.6 (4 d, CH), 75.5, 75.4 (2 s, C-OH), 44.7, 44.6, 44.2 
(3 d, CH), 30.0, 29.8 (2 q, CH3), 26.9, 26.8, 26.2 (3 t, 





mp 182-183 °C; 20a/20b = 1:4 (1H NMR). 
Anal. Calcd for C33H31N3O3: C, 76.59; H, 6.00; N, 8.12.  
Found: C, 76.6; H, 6.0; N, 8.1. 
CI-MS: m/z (%) = 518 (MH+, 90), 357 (12), 336 (100), 
200 (22), 183 (50), 175 (33), 105 (21). 
HRMS: m/z calcd for C33H32N3O3 (MH+): 518.2444; 
found: 518.2444. 
Compound 20a 
1H NMR (DMSO-d6): δ = 11.71 (br s, exch., 1 H, NH), 
8.14 (dd, J = 8, 1 Hz, 1 H, H5), 7.77-6.86 (m, 18 H, 
ArH), 6.73 (s, exch., 1 H, OH), 4.12 (q, J = 7 Hz, 1 H, 
CH), 3.66 (t, J = 7 Hz, 1 H, CH), 2.34-2.07 (m, 2 H, 
CH2), 1.33 (d, J = 7 Hz, 3 H, CH3), 1.07 (t, J = 7 Hz, 3 
H, CH3). 
13C NMR (DMSO-d6): δ = 172.8 (s, C=O), 162.4 (s, C4), 
158.6 (s, C2), 148.5 (s, C8a), 146.2, 145.1 (2 s, C1 of 
Ph's), 135.2 (d, C7), 129.5, 128.3, 128.1 (3 d, C3 of 
Ph's), 128.0 (d, C5), 127.4 (d, C6), 127.3 (d, C8), 126.6, 
126.0 (2 d, C4 of Ph's), 125.8, 125.7, 125.4 (3 d, C2 of 
Ph's), 120.3 (s, C4a), 79.1 (s, C-OH), 52.3 (d, CH), 41.6 
(d, CH), 25.8 (t, CH2), 14.3 (q, CH3), 12.7 (q, CH3). 
Compound 20b 
1H NMR (DMSO-d6): δ = 11.71 (br s, exch., 1 H, NH), 
8.12 (dd, J = 8, 1 Hz, 1 H, H5), 7.77-6.86 (m, 18 H, 
ArH), 6.73 (s, exch., 1 H, OH), 3.86 (q, J = 7 Hz, 1 H, 
CH), 3.63 (t, J = 7 Hz, 1 H, CH), 2.28-1.87 (m, 2 H, 
CH2), 1.21 (d, J = 7 Hz, 3 H, CH3), 0.90 (t, J = 7 Hz, 3 
H, CH3). 
13C NMR (DMSO-d6): δ = 173.3 (s, C=O), 162.7 (s, C4), 
158.5 (s, C2), 148.3 (s, C8a), 145.9, 145.0 (s, C1 of 
Ph's), 135.4 (d, C7), 129.2, 128.8, 128.5 (3 d, C3 of 
Ph's), 127.8 (d, C5), 127.6 (d, C6), 126.8 (d, C8), 126.3, 
126.1 (2 d, C4 of Ph's), 125.0, 124.8, 124.7 (3 d, C2 of 
Ph's), 120.1 (s, C4a), 79.0 (s, C-OH), 51.6 (d, CH), 41.6 




mp 90-93 °C; at least seven diastereoisomers (1H NMR). 
CI-MS: m/z (%) = 408 (MH+, 93), 336 (58), 273 (12), 
247 (84), 175 (100). 
HRMS: m/z calcd for C24H30N3O3 (MH+): 408.2287; 
found: 408.2287. 
1H NMR (CDCl3): δ = 8.94, 8.84, 8.83, 8.76, 8.64, 8.46, 
8.39 (7 s, exch., 1 H, NH), 8.19 (m, 1 H, H5), 7.77-6.90 
(m, 8 H, ArH), 6.13, 6.06, 5.81, 5.67, 5.23, 5.10, 4.56 (7 
s, exch., 1 H, OH), 3.65-3.58 (m, 1 H, CH), 3.11, 2.88, 
2.74, 2.70, 2.59, 2.46, 2.37 (7 q, J = 7 Hz, 1 H, CH), 
2.30-2.18 (m, 2 H, CH2), 1.92, 1.88, 1.85, 1.80 (4 s, 3 H, 
CH3), 1.69-0.52 (m, 11 H, CH2 and 3 CH3). 
13C NMR (CDCl3): δ = 174.3, 174.1, 173.2 (3 s, C=O), 
162.7, 162.5, 161.9, 161.7 (4 s, C4), 160.3, 160.1, 160.0 
(3 s, C2), 146.5, 146.3 (2 s, C8a), 138.9, 138.8, 138.7 (3 
s, C1 of Ph), 135.1, 135.0 (2 d, C7), 129.0, 128.9 (2 d, 
C3 of Ph), 128.1, 128.0 (2 d, C2 of Ph), 127.9, 127.8 (2 
d, C5), 127.7, 127.6 (2 d, C6), 127.3, 127.2 (2 d, C8), 
127.1, 127.0, 126.9 (3 d, C4 of Ph), 120.5, 120.4 (2 s, 
C4a), 74.6, 73.9, 73.8, 73.6 (4 s, C-OH), 53.3, 52.9, 52.8 
(3 d, CH), 41.4, 41.1, 40.6, 40.4 (4 d, CH), 34.4, 33.8, 
31.9, 26.8, 25.7, 25.6 (6 t, 2 CH2), 23.0, 22.6, 20.0 (3 q, 
CH3), 14.3, 14.1, 13.7, 13.5 (4 q, CH3), 12.4, 12.1, 12.0, 




mp 112-114 °C; four diastereoisomers (NMR). 
EI-MS: m/z (%) = 369 (12), 351 (43), 173 (18), 323 
(100), 258 (44). 
CI-MS: m/z (%) = 534 (MH+, 33), 371 (19), 352 (100), 
260 (16), 217 (18). 
HRMS: m/z calcd for C33H32N3O4 (MH+): 534.2393; 
found: 534.2397. 
1H NMR (DMSO-d6): δ = 11.47, 11.24 (2 br s, exch., 1 
H, NH), 8.07 (m, 1 H, H5), 7.79-6.83 (m, 19 H, ArH and 
OH), 5.35, 5.24 (2 q, J = 7 Hz, 1 H, CH), 4.28, 4.06, 
3.96, 3.84 (4 t, J = 7.5 Hz, 1 H, CH), 1.98-1.44 (m, 2 H, 
CH2), 1.82, 1.78, 1.75, 1.68 (4 d, J = 7 Hz, 3 H, CH3), 
0.71, 0.41, 0.35, 0.30 (4 t, J = 7.5 Hz, 3 H, CH3). 
13C NMR (DMSO-d6): δ = 173.5, 173.3, 172.6, 172.4 (4 
s, C=O), 161.8, 161.7, 161.4 (3 s, C4), 158.3, 158.2, 
158.1, 158.0 (4 s, C2), 157.3, 157.2, 157.1 (3 s, C1 of 
OPh), 148.6, 148.5, 148.4, 148.3 (4 s, C8a), 145.7, 
145.4, 144.7, 144. 5 (4 s, C1 of 2 Ph), 135.5, 135.4 (2 d, 
C7), 129.9, 129.8, 129.7 (3 d, C3 of OPh), 128.3, 128.0 
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(2 d, C3 of 2 Ph), 127.9, 127.8, 127.5 (3 d, C2 of 2 Ph), 
126.8, 126.5 (2 d, C5), 126.2, 126.1 (2 d, C6), 125.5, 
125.3 (2 d, C8), 125.1, 125.0 (2 d, C4 of 2 Ph), 121.9, 
121.6 (2 d, C4 of OPh), 119.9, 119.8 (2 s, C4a), 115.4, 
115.3, 114.6 (3 d, C2 of OPh), 79.7, 79.5, 79.2 (3 s, C-
OH), 73.6, 73.4, 71.8 (3 d, CH), 47.9, 74.5, 47.3, 47.1 (4 
d, CH), 22.9, 22.7 (2 t, CH2), 19.4, 19.1, 18.8, 18.5 (4 q, 




mp 158-159 °C; 23a/23b = 3:5 (1H NMR). 
EI-MS: m/z (%) = 323 (10), 230 (24), 187 (12), 160 (23), 
121 (44), 77 (100). 
CI-MS: m/z (%) = 458 (MH+, 9), 295 (48), 189 (53), 183 
(46), 166 (17), 122 (52), 106 (41), 91 (100). 
HRMS: m/z calcd for C27H28N3O4 (MH+): 458.2080; 
found: 458.2075. 
Compound 23a 
1H NMR (DMSO-d6): δ = 11.15 (br s, exch., 1 H, NH), 
7.94-6.75 (m, 14 H, ArH), 4.91 (q, J =7 Hz, 1 H, CH), 
4.79 (d, J = 3.5 Hz, exch., 1 H, OH), 4.74 (d, J = 5 Hz, 1 
H, CHOH), 2.87 (m, 1 H, CH), 1.63 (m, 1 H, 1 H of 
CH2), 1.48 (d, J = 7 Hz, 3 H, CH3), 1.32 (m, 1 H, 1 H of 
CH2), 0.40 (t, J = 7.5 Hz, 3 H, CH3). 
13C NMR (DMSO-d6): δ = 172.0 (s, C=O), 159.5 (s, C4), 
158.8 (s, C2), 157.1 (s, C1 of OPh), 145.9 (s, C8a), 
143.9 (s, C1 of Ph), 135.1 (d, C7), 129.6 (d, C3 of OPh), 
127.7 (d, C3 of Ph), 127.3 (d, C5), 127.0 (d, C2 of Ph), 
126.7 (d, C6), 126.4 (d, C8), 126.1 (d, C4 of Ph), 121.5 
(d, C4 of OPh), 120.4 (s, C4a), 115.1 (d, C2 of OPh), 
73.2 (d, CH), 72.1 (d, CH), 50.1 (d, CH), 20.5 (t, CH2), 
19.1 (q, CH3), 10.6 (q, CH3). 
Compound 23b 
1H NMR (DMSO-d6): δ = 11.15 (br s, exch., 1 H, NH), 
7.94-6.75 (m, 14 H, ArH), 5.15 (d, J = 3.5 Hz, exch., 1 
H, OH), 5.00 (q, J = 7 Hz, 1 H, CH), 4.88 (d, J = 4.5 Hz, 
1 H, CHOH), 2.98 (m, 1 H, CH), 1.86 (m, 1 H, 1 H of 
CH2), 1.43 (d, J = 7 Hz, 3 H, CH3), 1.23 (m, 1 H, 1 H of 
CH2), 0.34 (t, J = 7.5 Hz, 3 H, CH3). 
13C NMR (DMSO-d6): δ = 171.4 (s, C=O), 159.2 (s, C4), 
158.4 (s, C2), 157.0 (s, C1 of OPh), 146.3 (s, C8a), 
144.1 (s, C1 of Ph), 135.0 (d, C7), 129.5 (d, C3 of OPh), 
127.9 (d, C3 of Ph), 127.5 (d, C5), 126.9 (d, C2 of Ph), 
126.6 (d, C6), 126.3 (d, C8), 126.2 (d, C4 of Ph), 121.6 
(d, C4 of OPh), 120.6 (s, C4a), 115.5 (d, C2 of OPh), 
73.0 (d, CH), 72.2 (d, CH), 50.2 (d, CH), 18.7 (t, CH2), 
18.5 (q, CH3), 11.7 (q, CH3). 
2-(1-Ethyl-2-hydroxy-2-phenylpropyl)-3-(2-
phenoxypropionylamino)quinazolin-4(3H)-one (24) 
mp 79-81 °C; four diastereoisomers (NMR). 
EI-MS: m/z (%) = 323 (7), 230 (22), 173 (18), 160 (40), 
121 (32), 105 (49), 94 (22), 77 (100). 
CI-MS: m/z (%) = 472 (MH+, 5), 352 (17), 309 (18), 189 
(76), 138 (100), 122 (22), 91 (49). 
HRMS: m/z calcd for C27H28N3O4 (MH+): 472.2235; 
found: 472.2235. 
1H NMR (DMSO-d6): δ = 11.35 (br s, exch., 1 H, NH), 
8.23-6.78 (m, 14 H, ArH), 6.19, 6.11, 5.98 (3 s, exch., 1 
H, OH), 5.42-5.04 (m, 1 H, CH), 2.67-2.33 (m, 1 H, 
CH), 1.92-1.87 (m, 1 H, 1 H of CH2), 1.81, 1.79, 1.75, 
1.66 (4 d, J = 7 Hz, 3 H, CH3), 1.72, 1.70, 1.69, 1.66 (4 
s, CH3), 1.17 (m, 1 H, 1 H of CH2), 0.95, 0.76, 0.51, 0.37 
(4 t, J = 7.5 Hz, 3 H, CH3). 
13C NMR (DMSO-d6): δ = 172.4, 171.8, 171.3, 170.8 (4 
s, C=O), 162.1, 162.0, 160.6, 160.2 (4 s, C4), 159.0, 
158.9, 158.8, 158.5 (4 s, C2), 158.2, 158.1, 157.2, 157.0 
(4 s, C1 of OPh), 149.3, 147.0, 146.7, 146.6 (4 s, C8a), 
146.3, 145.7, 145.6, 145.1 (4 s, C1 of Ph), 135.5, 135.3, 
135.0, 134.6 (4 d, C7), 129.6, 129.5, 129.3, 128.1 (4 d, 
C3 of OPh), 128.0, 127.9, 127.8, 127.5 (4 d, C3 of Ph), 
127.4, 127.3, 127.2, 127.1 (4 d, C5), 126.9, 126.8, 126.7, 
126.6 (4 d, C2 of Ph), 126.4, 126.3, 126.1, 125.9 (4 d, 
C6), 125.1, 124.8 (2 d, C8), 124.7, 124.6 (2 d, C4 of Ph), 
121.7, 121.6, 121.5, 121.1 (4 d, C4 of OPh), 120.8, 
120.6, 120.4, 120.3 (4 s, C4a), 115.5, 115.2, 115.0, 114.9 
(4 d, C2 of OPh), 76.3, 76.2, 75.5, 75.4 (4 s, C-OH), 
73.4, 72.6, 72.0, 71.2 (4 d, CH), 53.7, 52.1, 51.4, 50.3 (4 
d, CH), 31.0, 30.8, 30.0, 29.7 (4 q, CH3), 22.3, 22.0, 
21.4, 20.9 (4 t, CH2), 19.3, 19.2, 19.0, 18.7 (4 q, CH3), 




mp 139-140 °C; four diastereoisomers (NMR) 
EI-MS: m/z (%) = 365 (51), 337 (100), 308 (20), 277 
(38). 
CI-MS: m/z (%) = 548 (MH+, 41), 371 (89), 366 (100). 
HRMS: m/z calcd for C34H34N3O4 (MH+): 548.2549; 
found: 548.2549. 
1H NMR (DMSO-d6): δ = 11.55, 11.51, 11.45, 11.28 (4 
s, exch., 1 H, NH), 8.10-6.85 (m, 20 H, ArH and OH), 
5.11, 5.02 (2 t, J = 7 Hz, 1 H, CH), 4.26, 4.05, 3.93, 3.82 
(4 t, J = 7.5 Hz, 1 H, CH), 2.22-1.43 (m, 4 H, 2 CH2), 
1.20, 1.09 (2 t, J = 7 Hz, 3 H, CH3), 0.68, 0.34, 0.30, 
0.28 (4 t, J = 7.5 Hz, 3 H, CH3). 
13C NMR (DMSO-d6): δ = 172.8, 171.7, 171.6 (3 s, 
C=O), 161.8, 161.3 (2 s, C4), 158.2, 158.0 (2 s, C2), 
157.7, 157.6 (2 s, C1 of OPh), 148.6, 148.5 (2 s, C8a), 
145.7, 144.4 (2 s, C1 of 2 Ph), 135.5, 135.4 (2 d, C7), 
129.9, 129.7 (2 d, C3 of OPh), 128.3, 128.1 (2 d, C3 of 2 
Ph), 127.9, 127.5 (2 d, C5), 126.8, 126.7 (2 d, C6), 
126.4, 125.5 (2 d, C8), 126.1, 125.5 (2 d, C4 of 2 Ph), 
125.3, 125.1 (2 d, C2 of 2 Ph), 121.7, 121.6 (2 d, C4 of 
OPh), 119.9 (s, C4a), 115.5, 114.7 (2 d, C2 of OPh), 
79.7, 79.2 (2 s, C-OH), 78.7, 76.9 (2 d, CH), 47.9, 47.8, 
47.7 (3 d, CH), 26.3, 25.8 (2 t, CH2), 22.8, 22.7 (2 t, 
CH2), 12.7, 12.0 (2 q, CH3), 9.7, 9.6, 9.5, 9.4 (4 q, CH3). 
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mp 136-137 °C; 26a/26b = 3:5 (1H NMR). 
EI-MS: m/z (%) = 365 (62), 337 (100), 308 (22), 272 
(45). 
CI-MS: m/z (%) = 472 (MH+, 16), 295 (33), 197 (70), 
189 (100), 180 (18), 139 (18), 136 (23), 105 (82), 88 
(27). 
HRMS: m/z calcd for C27H28N3O4 (MH+): 472.2235; 
found: 472.2230. 
Compound 26a 
1H NMR (DMSO-d6): δ = 11.26 (br s, exch., 1 H, NH), 
8.13-6.97 (m, 15 H, ArH and OH), 5.11 (d, J = 4 Hz, 1 
H, CHOH), 4.94 (t, J = 7 Hz, 1 H, CH), 3.08 (m, 1 H, 
CH), 2.14-1.38 (m, 4 H, 2 CH2), 1.17 (t, J = 7 Hz, 3 H, 
CH3), 0.58 (t, J = 7.5 Hz, 3 H, CH3). 
13C NMR (DMSO-d6): δ = 171.3 (s, C=O), 159.6 (s, C4), 
158.8 (s, C2), 157.5 (s, C1 of OPh), 145.9 (s, C8a), 
143.9 (s, C1 of Ph), 135.2 (d, C7), 129.6 (d, C3 of OPh), 
127.7 (d, C3 of Ph), 127.3 (d, C5), 126.9 (d, C2 of Ph), 
126.6 (d, C6), 126.4 (d, C8), 126.3 (d, C4 of Ph), 121.6 
(d, C4 of OPh), 120.4 (s, C4a), 115.4 (d, C2 of OPh), 
78.2 (d, CH), 72.1 (d, CH), 48.4 (d, CH), 26.1 (t, CH2), 
20.5 (t, CH2), 15.5 (q, CH3), 10.5 (q, CH3). 
Compound 26b 
1H NMR (DMSO-d6): δ = 11.42 (br s, exch., 1 H, NH), 
8.13-6.97 (m, 15 H, ArH and OH), 5.34 (d, J = 4 Hz, 1 
H, CHOH), 4.98 (t, J = 7 Hz, 1 H, CH), 3.12 (m, 1 H, 
CH), 2.14-1.38 (m, 4 H, 2 CH2), 1.09 (t, J = 7 Hz, 3 H, 
CH3), 0.54 (t, J = 7.5 Hz, 3 H, CH3) 
13C NMR (DMSO-d6): δ = 170.7 (s, C=O), 159.2 (s, C4), 
158.4 (s, C2), 157.5 (s, C1 of OPh), 146.3 (s, C8a), 
144.0 (s, C1 of Ph), 135.0 (d, C7), 129.5 (d, C3 of OPh), 
127.9 (d, C3 of Ph), 127.5 (d, C5), 127.0 (d, C2 of Ph), 
126.7 (d, C6), 126.4 (d, C8), 126.3 (d, C4 of Ph), 121.7 
(d, C4 of OPh), 120.6 (s, C4a), 115.7 (d, C2 of OPh), 
77.3 (d, CH), 72.9 (d, CH), 50.1 (d, CH), 25.6 (t, CH2), 




mp 105-107 °C; 27a/27b = 4:5 (1H NMR). 
EI-MS: m/z (%) = 365 (19), 337 (25), 272 (10), 244 (53), 
230 (100), 214 (24), 202 (27). 
EI-MS: m/z (%) = 486 (MH+, 33), 366 (15), 309 (100). 
HRMS: m/z calcd for C29H32N3O4 (MH+): 486.2393; 
found: 486.2394. 
Compound 27a 
1H NMR (DMSO-d6): δ = 11.34 (br s, exch., 1 H, NH), 
8.21-6.94 (m, 14 H, ArH), 5.27 (s, exch., 1 H, OH), 5.06-
5.00 (m, 1 H, CH), 3.44-3.41 (m, 1 H, CH), 2.15-1.56 
(m, 4 H, 2 CH2), 1.19 (s, 3 H, CH3), 0.85 (t, J = 7 Hz, 3 
H, CH3), 0.23 (t, J = 7.5 Hz, 3 H, CH3). 
13C NMR (DMSO-d6): δ = 172.2 (s, C=O), 160.0 (s, C4), 
158.4 (s, C2), 157.5 (s, C1 of OPh), 147.0 (s, C8a), 
145.7 (s, C1 of Ph), 135.3 (d, C7), 129.7 (d, C3 of OPh), 
127.9 (d, C3 of Ph), 127.4 (d, C5), 127.2 (d, C6), 126.6 
(d, C8), 124.7 (d, C2 of Ph), 121.5 (d, C4 of Ph), 120.3 
(d, C4 of OPh), 119.4 (s, C4a), 115.1 (d, C2 of OPh), 
76.9 (d, CH), 75.3 (s, C-OH), 50.2 (d, CH), 29.5 (q, 
CH3), 25.9 (t, CH2), 21.9 (t, CH2), 11.9 (q, CH3), 9.7 (q, 
CH3). 
Compound 27b 
1H NMR (DMSO-d6): δ = 11.34 (br s, exch., 1 H, NH), 
8.21-6.94 (m, 14 H, ArH), 6.01 (s, exch., 1 H, OH), 5.06-
5.00 (m, 1 H, CH), 3.10-3.08 (m, 1 H, CH), 2.15-1.56 
(m, 4 H, 2 CH2), 1.28 (s, 3 H, CH3), 1.15 (t, J = 7 Hz, 3 
H, CH3), 0.33 (t, J = 7.5 Hz, 3 H, CH3). 
13C NMR (DMSO-d6): δ = 170.6 (s, C=O), 162.1 (s, C4), 
158.6 (s, C2), 157.6 (s, C1 of OPh), 146.7 (s, C8a), 
145.1 (s, C1 of Ph), 135.5 (d, C7), 129.5 (d, C3 of OPh), 
128.0 (d, C3 of Ph), 127.5 (d, C5), 127.1 (d, C6), 126.5 
(d, C8), 125.1 (d, C2 of Ph), 121.5 (d, C4 of Ph), 120.6 
(d, C4 of OPh), 120.4 (s, C4a), 115.4 (d, C2 of OPh), 
78.2 (d, CH), 75.5 (s, C-OH), 52.1 (d, CH), 30.8 (q, 




We thank the EPSRC Mass Spectroscopy Service, University of 
Wales Swansea, for recording the mass spectra.  We also thank the 
EPSRC, the Higher Education Funding Council for Wales (ELWa-
HEFCW) and the University of Wales Swansea for grants that 
enabled the purchase and upgrading of NMR equipment used in 
the course of this work.  G. A. El-Hiti thanks the University of 
Wales Swansea for financial support and the Royal Society of 
Chemistry for an international author grant. 
References 
(1) Permanent address; Department of Chemistry, Faculty of 
Science, Tanta University, Tanta 31527, Egypt. 
(2) (a) Beak, P.; Zajdel, W. J.; Reitz, D. B. Chem. Rev. 1984, 
84, 471. (b) Snieckus, V. Chem. Rev. 1990, 90, 879. (c) El-
Hiti, G. A. Heterocycles 2000, 53, 1839. (d) Mongin, F.; 
Quéguiner, G. Tetrahedron 2001, 57, 4059. (e) Turck, A.; 
Plé, N.; Mongin, F.; Quéguiner, G. Tetrahedron 2001, 57, 
4489. (f) Anctil, E. J.-G.; Snieckus, V. J. Organomet. Chem. 
2002, 653, 150. (g) Smith, K.; El-Hiti, G. A. Curr. Org. 
Synth. 2004, 1, in press. (h) Chinchilla, R.; Nájera, C.; Yus, 
M. Chem. Rev. 2004, in press. 
(3) See for example: (a) Choppin, S.; Gros, P.; Fort, Y. Org. 
Lett. 2000, 2, 803. (b) Kondo, Y.; Asai, M.; Miura, T.; 
Uchiyama, M.; Sakamoto, T. Org. Lett. 2001, 3, 13. (c) 
Rebstock, A.-S.; Mongin, F.; Trécourt, F.; Quéguiner, G. 
Tetrahedron Lett. 2002, 43, 767. (d) Rhonnstad, P.; 
Wensbo, D. Tetrahedron Lett. 2002, 43, 3137. (e) Mukher-
jee, C.; De, A. Synlett 2002, 325. (f) Cuperly, D.; Gros, P.; 
Fort, Y. J. Org. Chem. 2002, 67, 238. (g) Gros, P.; Louërat, 
F.; Fort, Y. Org. Lett. 2002, 4, 175. (h) Toudic, F.; Plé, N.; 
Turck, A.; Quéguiner, G. Tetrahedron 2002, 58, 238. (i) 
14 PAPER  
Template for SYNLETT and SYNTHESIS © Thieme  Stuttgart · New York 2004-05-13 page 14 of 15 
Bunch, L.; Krogsgaard-Larsen, P.; Madsen, U. J. Org. 
Chem. 2002, 67, 2375. (j) Katritzky, A. R.; Manju, K.; 
Steel, P. J. J. Org. Chem. 2003, 68, 407. (k) Gros, P.; Chop-
pin, S.; Fort, Y. J. Org. Chem. 2003, 68, 2243. (l) El-Hiti, 
G. A. Synthesis 2004, 363. (m) Cabiddu, M. C.; Cabiddu, 
S.; Cadoni, E.; De Montis, S.; Fattuoni, C.; Melis, S. Tetra-
hedron 2004, 60, 3915. 
(4) Murray, T. P.; Hay, J. V.; Protlock, D. E.; Wolfe, J. F. J. 
Org. Chem. 1974, 39, 595. 
(5) Rathman, T. L.; Sleevi, M. C.; Krafft, M. F.; Wolfe, J. F. J. 
Org. Chem. 1980, 45, 2169. 
(6) Smith, K.; El-Hiti, G. A.; Abdel-Megeed, M. F.; Abdo, M. 
A. Collect. Czech. Chem. Commun. 1999, 64, 515. 
(7) Smith, K.; El-Hiti, G. A.; Abdel-Megeed, M. F.; Abdo, M. 
A. J. Org. Chem. 1996, 61, 656. 
(8) El-Hiti, G. A. Monatsh. Chem. 2004, 135, 323. 
(9) Smith, K.; El-Hiti, G. A.; Abdel-Megeed, M. F.; Abdo, M. 
A. J. Org. Chem. 1996, 61, 647. 
(10) Smith, K.; El-Hiti, G. A.; Abdo, M. A.; Abdel-Megeed, M. 
F. J. Chem. Soc. Perkin Trans. 1 1995, 1029. 
(11) Plé, N.; Turck, A.; Chapoulaud, V.; Quéguiner, G. Tetrahe-
dron 1997, 53, 2871. 
(12) Dai, X.; Virgil, S. Tetrahedron Asymmetry 1999, 10, 25. 
(13) Chapoulaud, V. G.; Salliot, I.; Plé, N.; Turck, A.; 
Quéguiner, G. Tetrahedron 1999, 55, 5389. 
(14) See for example: (a) Honda, G.; Tabata, M.; Tsuda, M. 
Planta Med. 1979, 37, 172. (b) Johne, S. Prog. Drug Res. 
1982, 26, 259. (c) Johne, S. The Alkaloids 1986, 29, 99. (d) 
Schlecker, R.; Treiber, H. J.; Behl, B.; Hofmann, H. P. Ger. 
Offen 4 241 563, 1994; Chem. Abstr. 1994, 121, 230787. 
(e) Barker, A. J. Eur. Patent 635 498, 1995; Chem. Abstr. 
1995, 122, 214099. (f) Barker, A. J.; Johnstine, C. PCT Int 
Appl WO 300 44, 1997; Chem. Abstr. 1995, 127, 220671. 
(g) Hour, M.-J.; Huang, L.-J.; Kuo, S.-C.; Xia, Y.; Bastow, 
K.; Nakanishi, Y.; Hamel, E.; Lee, K.-H. J. Med. Chem. 
2000, 43, 4479. (h) Ho, N.; Harapanhalli, R. S.; Dahman, 
B. A.; Chen, K.; Wang, K. Bioconjugate Chem. 2002, 13, 
357. 
(15) See for example: (a) Smith, K.; El-Hiti, G. A.; Hamilton, A. 
J. Chem. Soc., Perkin Trans. 1 1998, 4041. (b) Smith, K.; 
El-Hiti, G. A.; Pritchard, G. J.; Hamilton, A. J. Chem. Soc., 
Perkin Trans. 1 1999, 2299. (c) Smith, K.; El-Hiti, G. A.; 
Shukla, A. P. J. Chem. Soc., Perkin Trans. 1 1999, 2305. 
(d) Smith, K.; El-Hiti, G. A.; Abdel-Megeed, M. F. Russ. J. 
Org. Chem., 2003, 39, 430. (e) Smith, K.; El-Hiti, G. A.; 
Hawes, A. C. Synthesis 2003, 2047. (f) Smith, K.; El-Hiti, 
G. A.; Mahgoub, S. A. Synthesis 2003, 2345. (g) El-Hiti, G. 
A. Synthesis 2003, 2799. 
(16) Sammour, A.; Selim, M.; El Kasaby, M.; Abdalla, M. Acta 
Chim. (Budapest) 1973, 78, 293; Chem. Abstr. 1973, 79, 
137061. 
(17) (a) Essawy, A.; El-Hashash, M. A.; El-Gendy, A. M.; 
Hamad, M. M. M. Indian J. Chem. 1982, 21B, 593. 
(18) El-Hiti, G. A. Spectrosc. Lett., 1999, 32, 671. 
(19) Vogel’s Textbook of Practical Organic Chemistry: 5th Edn, 
Longman, Harlow 1989. 
(20) Perrin, D. D.; Armarego, W. L. F.; Perrin, D. R. Purifica-
tion of Laboratory Chemicals, Pergamon, 3rd Edn, Butter-
worth Heinemann, Oxford, 1988. 
 
15 PAPER  
Template for SYNLETT and SYNTHESIS © Thieme  Stuttgart · New York 2004-05-13 page 15 of 15 














iii, NH4Cl  
 
 
Manuscript submission checklist 
 • Statement of significance of work. 
 • Full mailing address, telephone and fax numbers, and email address of the corresponding author. 
 • Paper save as a PDF file. 
 • Original Word file. 
 • Original graphic files. 
 • Graphical abstract. 
